Prof. Guowen Wang 王国文
Chief Physician, Professor
Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute & Hospital, Tianjin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment of malignant bone and spinal tumors, comprehensive care for soft tissue tumors, limb-salvage surgery, and diagnosis of bone and soft tissue tumors.
Dr. Wang is a Chief Physician, Professor, and Department Head with over 20 years of clinical, teaching, and research experience. Holding an MD and postdoctoral fellowship in bone tumors, Dr. Wang specializes in microsurgery and reconstruction. As one of the earliest specialists in China to use radiofrequency ablation for bone tumors, Dr. Wang has conducted academic exchanges at MD Anderson and Moffitt Cancer Center. Research focuses on dedifferentiated chondrosarcoma mechanisms.
Professional roles
- Member, Bone and Soft Tissue Tumor Group, Oncology Branch, Chinese Medical Association
- Member, Bone Metastasis Cancer Group, Sarcoma Professional Committee, China Anti-Cancer Association
- Deputy Leader, Bone Tumor Group, Orthopedics Branch, Tianjin Medical Association
- Member, Osteoporosis Professional Committee, China Gerontological Society
Name order: in Chinese the family name comes first (Wang Guowen). Papers usually list the name as Guowen Wang or Wang G.
Selected publications
77 papers on PubMed matched by name and affiliation; 28 as first or senior author since 2016. Most recent first- or senior-author papers:
- Oncogene, 2026 (senior author): KIFC1 engages RUNX2/TGF-β signaling to promote lung cancer bone metastasis via disrupting bone homeostasis. PubMed 42791262
- Oncol Lett, 2026 (senior author): TBX20 regulates epithelial-mesenchymal transition, maintains tumor stemness and immune factor expression, and promotes immune escape in lung cancer. PubMed 41993851
- Cancer Immunol Immunother, 2026 (senior author): Integrating single-cell and bulk transcriptomes to reveal prognostic and immunological features of ecDNA-related genes in osteosarcoma. PubMed 42047819
- Curr Med Chem, 2026 (senior author): Aspirin Downregulates PDE4D to Inhibit Malignant Progression of Osteosarcoma through the NF-κB/p65 Pathway. PubMed 41540519
- Cancer Lett, 2025 (senior author): METTL3-mediated m6A modification of LINC00520 confers glycolysis and chemoresistance in osteosarcoma via suppressing ubiquitination of ENO1. PubMed 39168299
- J Cancer, 2025 (senior author): The effect of intraoperative radiotherapy in musculoskeletal malignancy: A population study from US SEER database. PubMed 39744579
- Aging (Albany NY), 2024 (senior author): Construction of an oxidative phosphorylation-related gene signature for predicting prognosis and identifying immune infiltration in osteosarcoma. PubMed 38506898
- Int J Cancer, 2024 (senior author): Twenty-year outcome of prevalence, incidence, mortality and survival rate in patients with malignant bone tumors. PubMed 37596989
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion